Mr. Chair, the purpose of this amendment is to essentially reinstate the application process under CAMR, which of course, as you know, requires, in applying for a compulsory licence, including certain information: the version of the pharmaceutical product, the quantity of the product to be exported, the name of the patent holder, the name of the importing country, and the name of the importing entity. Deleting lines 15 to 18 in clause 4 will accomplish that purpose and will reinstate the original application process.
On October 28th, 2010. See this statement in context.